Cravath Publishes Summer 2026 Issue of Alumni Journal
Sarah W.
Colangelo
Of Counsel, Executive Compensation and Benefits
Sarah W. Colangelo focuses her practice on executive compensation and employee benefit matters, principally in connection with mergers and acquisitions, securities offerings and other corporate transactions.
Ms. Colangelo’s notable transactions include representing:
- AerCap in its $30 billion acquisition of GE Capital Aviation Services;
- Northrop Grumman in the $3.4 billion sale of its federal IT and mission support business to Veritas Capital;
- The special committee of the board of Eidos Therapeutics in its $2.83 billion merger with BridgeBio Pharma;
- Bharti in the acquisition of, and $1 billion investment in, OneWeb by a consortium led by Bharti and Her Majesty’s Government;
- Disney in Endemol Shine’s acquisition by Banijay Group;
- Parker Hannifin in its $3.7 billion acquisition of LORD;
- Occidental Petroleum in its $57 billion acquisition of Anadarko, topping Anadarko’s original agreement with Chevron;
- Time Warner in its $109 billion sale to AT&T;
- Johnson & Johnson in its $30 billion acquisition of Actelion;
- Technicolor in the $475 million sale of its Patent Licensing business and the sale of its Research & Innovation activity to InterDigital;
- CommScope in its $1 billion investment from The Carlyle Group as part of CommScope’s $7.4 billion acquisition of ARRIS;
- AveXis in its $8.7 billion acquisition by Novartis;
- Montpelier Re Holdings in its sale to Endurance Specialty Holdings; and
- Sapient in its $3.7 billion acquisition by Publicis.
Ms. Colangelo considers Charleston, South Carolina her home. She received a B.A. summa cum laude from Duke University in 2007 where she was elected to Phi Beta Kappa and a J.D. magna cum laude from Georgetown Law School in 2014, where she was the Editor‑in‑Chief of The Tax Lawyer and elected to the Order of the Coif. Prior to attending law school, Ms. Colangelo served in the United States Navy. Ms. Colangelo joined Cravath in 2014 and was named of counsel in 2023.
Ms. Colangelo’s notable transactions include representing:
- AerCap in its $30 billion acquisition of GE Capital Aviation Services;
- Northrop Grumman in the $3.4 billion sale of its federal IT and mission support business to Veritas Capital;
- The special committee of the board of Eidos Therapeutics in its $2.83 billion merger with BridgeBio Pharma;
- Bharti in the acquisition of, and $1 billion investment in, OneWeb by a consortium led by Bharti and Her Majesty’s Government;
- Disney in Endemol Shine’s acquisition by Banijay Group;
- Parker Hannifin in its $3.7 billion acquisition of LORD;
- Occidental Petroleum in its $57 billion acquisition of Anadarko, topping Anadarko’s original agreement with Chevron;
- Time Warner in its $109 billion sale to AT&T;
- Johnson & Johnson in its $30 billion acquisition of Actelion;
- Technicolor in the $475 million sale of its Patent Licensing business and the sale of its Research & Innovation activity to InterDigital;
- CommScope in its $1 billion investment from The Carlyle Group as part of CommScope’s $7.4 billion acquisition of ARRIS;
- AveXis in its $8.7 billion acquisition by Novartis;
- Montpelier Re Holdings in its sale to Endurance Specialty Holdings; and
- Sapient in its $3.7 billion acquisition by Publicis.
Ms. Colangelo considers Charleston, South Carolina her home. She received a B.A. summa cum laude from Duke University in 2007 where she was elected to Phi Beta Kappa and a J.D. magna cum laude from Georgetown Law School in 2014, where she was the Editor‑in‑Chief of The Tax Lawyer and elected to the Order of the Coif. Prior to attending law school, Ms. Colangelo served in the United States Navy. Ms. Colangelo joined Cravath in 2014 and was named of counsel in 2023.
Education
-
J.D., 2014, Georgetown University Law CenterOrder of the Coif, magna cum laude
-
B.A., 2007, Duke UniversityPhi Beta Kappa, summa cum laude
Admitted In
- New York
Deals & Cases
October 08, 2026
Viatris’s $1.65 Billion Acquisition of Pacira
On October 8, 2026, Viatris Inc. (“Viatris”), a global healthcare company, and Pacira BioSciences, Inc. (“Pacira”), a leader in innovative non‑opioid pain therapies, announced that they have entered into a definitive agreement under which Viatris has agreed to acquire all of the outstanding shares of common stock of Pacira for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion. Cravath is representing Viatris in connection with the transaction.
Deals & Cases
October 01, 2026
Corteva’s Spin‑Off of Seed and Genetics Business
On October 1, 2026, Corteva, Inc. (“Corteva”) announced it has successfully spun off its advanced seed and genetics business as a new public company, Vylor, Inc., and will move forward as a leading, pure‑play global crop protection company. Cravath is representing Corteva in connection with the transaction.
Deals & Cases
August 11, 2026
Viatris’s Sale of TYRVAYA to Harrow
On August 6, 2026, Harrow, a leading provider of ophthalmic disease management solutions in North America, announced that it has entered into a definitive agreement to acquire TYRVAYA® (varenicline solution) nasal spray 0.03 mg from Viatris Inc. (“Viatris”), a global healthcare company. TYRVAYA is a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease (DED) and is currently approved in the U.S., China, and Taiwan, with marketing authorization applications pending in other countries. Under the terms of the agreement, Harrow will pay $30 million in cash at closing and up to $70 million in contingent milestone payments tied to TYRVAYA's net sales, for a potential total consideration of up to $100 million. Cravath is representing Viatris in connection with the transaction.
Deals & Cases
June 29, 2026
Martin Marietta’s $13.5 Billion Combination with Lhoist North America
On June 29, 2026, Martin Marietta Materials, Inc. (“Martin Marietta”), a leading supplier of aggregates and other building materials, announced that it has entered into a definitive agreement to combine with Lhoist North America, Inc. (“Lhoist North America”), a leading producer of hi‑calcium lime, dolomitic lime and industrial mineral products and a subsidiary of Lhoist Group, for $13.5 billion in cash and shares of Martin Marietta common stock. The transaction is expected to be completed in the second half of 2026, subject to regulatory approvals. Cravath is representing Martin Marietta in connection with the transaction.
Deals & Cases
February 24, 2026
ADT’s Acquisition of Origin
On February 24, 2026, ADT, a leading provider of security, interactive and smart home solutions serving residential and small business customers in the U.S., announced it has acquired Origin Wireless, Inc. (“Origin”), bringing Origin’s AI sensing platform and related intellectual property into the ADT ecosystem. The purchase price for the transaction was $170 million in cash, subject to customary purchase price adjustments. Cravath is representing ADT in connection with the transaction.
Sarah W. Colangelo focuses her practice on executive compensation and employee benefit matters, principally in connection with mergers and acquisitions, securities offerings and other corporate transactions.
Ms. Colangelo’s notable transactions include representing:
- AerCap in its $30 billion acquisition of GE Capital Aviation Services;
- Northrop Grumman in the $3.4 billion sale of its federal IT and mission support business to Veritas Capital;
- The special committee of the board of Eidos Therapeutics in its $2.83 billion merger with BridgeBio Pharma;
- Bharti in the acquisition of, and $1 billion investment in, OneWeb by a consortium led by Bharti and Her Majesty’s Government;
- Disney in Endemol Shine’s acquisition by Banijay Group;
- Parker Hannifin in its $3.7 billion acquisition of LORD;
- Occidental Petroleum in its $57 billion acquisition of Anadarko, topping Anadarko’s original agreement with Chevron;
- Time Warner in its $109 billion sale to AT&T;
- Johnson & Johnson in its $30 billion acquisition of Actelion;
- Technicolor in the $475 million sale of its Patent Licensing business and the sale of its Research & Innovation activity to InterDigital;
- CommScope in its $1 billion investment from The Carlyle Group as part of CommScope’s $7.4 billion acquisition of ARRIS;
- AveXis in its $8.7 billion acquisition by Novartis;
- Montpelier Re Holdings in its sale to Endurance Specialty Holdings; and
- Sapient in its $3.7 billion acquisition by Publicis.
Ms. Colangelo considers Charleston, South Carolina her home. She received a B.A. summa cum laude from Duke University in 2007 where she was elected to Phi Beta Kappa and a J.D. magna cum laude from Georgetown Law School in 2014, where she was the Editor‑in‑Chief of The Tax Lawyer and elected to the Order of the Coif. Prior to attending law school, Ms. Colangelo served in the United States Navy. Ms. Colangelo joined Cravath in 2014 and was named of counsel in 2023.
Ms. Colangelo’s notable transactions include representing:
- AerCap in its $30 billion acquisition of GE Capital Aviation Services;
- Northrop Grumman in the $3.4 billion sale of its federal IT and mission support business to Veritas Capital;
- The special committee of the board of Eidos Therapeutics in its $2.83 billion merger with BridgeBio Pharma;
- Bharti in the acquisition of, and $1 billion investment in, OneWeb by a consortium led by Bharti and Her Majesty’s Government;
- Disney in Endemol Shine’s acquisition by Banijay Group;
- Parker Hannifin in its $3.7 billion acquisition of LORD;
- Occidental Petroleum in its $57 billion acquisition of Anadarko, topping Anadarko’s original agreement with Chevron;
- Time Warner in its $109 billion sale to AT&T;
- Johnson & Johnson in its $30 billion acquisition of Actelion;
- Technicolor in the $475 million sale of its Patent Licensing business and the sale of its Research & Innovation activity to InterDigital;
- CommScope in its $1 billion investment from The Carlyle Group as part of CommScope’s $7.4 billion acquisition of ARRIS;
- AveXis in its $8.7 billion acquisition by Novartis;
- Montpelier Re Holdings in its sale to Endurance Specialty Holdings; and
- Sapient in its $3.7 billion acquisition by Publicis.
Ms. Colangelo considers Charleston, South Carolina her home. She received a B.A. summa cum laude from Duke University in 2007 where she was elected to Phi Beta Kappa and a J.D. magna cum laude from Georgetown Law School in 2014, where she was the Editor‑in‑Chief of The Tax Lawyer and elected to the Order of the Coif. Prior to attending law school, Ms. Colangelo served in the United States Navy. Ms. Colangelo joined Cravath in 2014 and was named of counsel in 2023.
Education
-
J.D., 2014, Georgetown University Law CenterOrder of the Coif, magna cum laude
-
B.A., 2007, Duke UniversityPhi Beta Kappa, summa cum laude
Admitted In
- New York
Deals & Cases
October 08, 2026
Viatris’s $1.65 Billion Acquisition of Pacira
On October 8, 2026, Viatris Inc. (“Viatris”), a global healthcare company, and Pacira BioSciences, Inc. (“Pacira”), a leader in innovative non‑opioid pain therapies, announced that they have entered into a definitive agreement under which Viatris has agreed to acquire all of the outstanding shares of common stock of Pacira for $36.50 per share in cash, representing an aggregate equity value of $1.65 billion. Cravath is representing Viatris in connection with the transaction.
Deals & Cases
October 01, 2026
Corteva’s Spin‑Off of Seed and Genetics Business
On October 1, 2026, Corteva, Inc. (“Corteva”) announced it has successfully spun off its advanced seed and genetics business as a new public company, Vylor, Inc., and will move forward as a leading, pure‑play global crop protection company. Cravath is representing Corteva in connection with the transaction.
Deals & Cases
August 11, 2026
Viatris’s Sale of TYRVAYA to Harrow
On August 6, 2026, Harrow, a leading provider of ophthalmic disease management solutions in North America, announced that it has entered into a definitive agreement to acquire TYRVAYA® (varenicline solution) nasal spray 0.03 mg from Viatris Inc. (“Viatris”), a global healthcare company. TYRVAYA is a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease (DED) and is currently approved in the U.S., China, and Taiwan, with marketing authorization applications pending in other countries. Under the terms of the agreement, Harrow will pay $30 million in cash at closing and up to $70 million in contingent milestone payments tied to TYRVAYA's net sales, for a potential total consideration of up to $100 million. Cravath is representing Viatris in connection with the transaction.
Deals & Cases
June 29, 2026
Martin Marietta’s $13.5 Billion Combination with Lhoist North America
On June 29, 2026, Martin Marietta Materials, Inc. (“Martin Marietta”), a leading supplier of aggregates and other building materials, announced that it has entered into a definitive agreement to combine with Lhoist North America, Inc. (“Lhoist North America”), a leading producer of hi‑calcium lime, dolomitic lime and industrial mineral products and a subsidiary of Lhoist Group, for $13.5 billion in cash and shares of Martin Marietta common stock. The transaction is expected to be completed in the second half of 2026, subject to regulatory approvals. Cravath is representing Martin Marietta in connection with the transaction.
Deals & Cases
February 24, 2026
ADT’s Acquisition of Origin
On February 24, 2026, ADT, a leading provider of security, interactive and smart home solutions serving residential and small business customers in the U.S., announced it has acquired Origin Wireless, Inc. (“Origin”), bringing Origin’s AI sensing platform and related intellectual property into the ADT ecosystem. The purchase price for the transaction was $170 million in cash, subject to customary purchase price adjustments. Cravath is representing ADT in connection with the transaction.
Cravath Bicentennial
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2026 Cravath, Swaine & Moore LLP.